Skip to main content
Top
Published in: BMC Neurology 1/2022

01-12-2022 | Stroke | Research

Inactivated COVID-19 vaccine induced acute stroke-like focal neurologic symptoms: a case series

Authors: Duangnapa Roongpiboonsopit, Chichaya Nithisathienchai, Wasan Akarathanawat, Krittanon Lertutsahakul, Jarturon Tantivattana, Anand Viswanathan, Nijasri Charnnarong Suwanwela

Published in: BMC Neurology | Issue 1/2022

Login to get access

Abstract

Background

A subgroup of individuals experienced stroke-like symptoms after receiving an inactivated COVID-19 vaccine. We present clinical characteristics, neuroimaging, and outcome of these patients.

Methods

Medical personals who had neurological symptoms after receiving inactivated COVID-19 vaccine were enrolled. Clinical, laboratory investigation and neuroimaging were collected. Subjects were prospectively followed-up on clinical and neuroimaging to detect brain parenchymal or cerebrovascular abnormality.

Results

Nineteen out of 385 subjects (4.9%) developed neurological symptoms after vaccination. There was a female predominance (89.5%) with mean age of 34 ± 7.5 years. Majority of patients (52.6%) had symptoms within 60 min after vaccination. The most common neurological symptoms were numbness (94.7%) followed by headache (52.6%) and weakness (47.4%). The most common neurological signs were sensory deficit (79%) followed by motor weakness (52.6%) and tongue deviation (26.3%). Recurrent headache was observed in most patients (89.5%) during followed up. Serial brain imaging was done in all patients with median follow-up interval of 18 days. There was no evidence of acute brain infarction in any of the patients, 84.2% had no vascular abnormality, 15.8% had transient focal narrowing of cerebral vessels. Outcome was favorable, modified ranking scale 0–1 for all patients at 4 weeks after vaccination.

Conclusions

Transient focal neurological symptoms and deficits can be found after COVID-19 vaccination. However, benefit to stop COVID-19 pandemic by vaccination is outweighed by these seemingly reversible side effects. The pathophysiology underlined these phenomena should be further investigated.
Appendix
Available only for authorised users
Literature
2.
go back to reference Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35–45.CrossRef Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35–45.CrossRef
3.
go back to reference Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951–60.CrossRef Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951–60.CrossRef
4.
go back to reference Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51.CrossRef Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51.CrossRef
5.
go back to reference Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–92.CrossRef Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–92.CrossRef
6.
go back to reference Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser MG. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain. 2007;130(Pt 12):3091–101.CrossRef Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser MG. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain. 2007;130(Pt 12):3091–101.CrossRef
7.
go back to reference Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007;146(1):34–44.CrossRef Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007;146(1):34–44.CrossRef
8.
go back to reference Topcuoglu MA, McKee KE, Singhal AB. Gender and hormonal influences in reversible cerebral vasoconstriction syndrome. Eur Stroke J. 2016;1(3):199–204.CrossRefPubMedCentral Topcuoglu MA, McKee KE, Singhal AB. Gender and hormonal influences in reversible cerebral vasoconstriction syndrome. Eur Stroke J. 2016;1(3):199–204.CrossRefPubMedCentral
9.
go back to reference Wolff V, Ducros A. Reversible cerebral vasoconstriction syndrome without typical thunderclap headache. Headache. 2016;56(4):674–87.CrossRef Wolff V, Ducros A. Reversible cerebral vasoconstriction syndrome without typical thunderclap headache. Headache. 2016;56(4):674–87.CrossRef
10.
go back to reference Singhal AB, Hajj-Ali RA, Topcuoglu MA, Fok J, Bena J, Yang D, et al. Reversible cerebral vasoconstriction syndromes: analysis of 139 cases. Arch Neurol. 2011;68(8):1005–12.CrossRef Singhal AB, Hajj-Ali RA, Topcuoglu MA, Fok J, Bena J, Yang D, et al. Reversible cerebral vasoconstriction syndromes: analysis of 139 cases. Arch Neurol. 2011;68(8):1005–12.CrossRef
11.
go back to reference Chen SP, Fuh JL, Wang SJ, Chang FC, Lirng JF, Fang YC, et al. Magnetic resonance angiography in reversible cerebral vasoconstriction syndromes. Ann Neurol. 2010;67(5):648–56.PubMed Chen SP, Fuh JL, Wang SJ, Chang FC, Lirng JF, Fang YC, et al. Magnetic resonance angiography in reversible cerebral vasoconstriction syndromes. Ann Neurol. 2010;67(5):648–56.PubMed
12.
go back to reference Headache Classification Committee of the International Headache S. The International classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.CrossRef Headache Classification Committee of the International Headache S. The International classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.CrossRef
13.
go back to reference Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022;43(1):3–40.CrossRef Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022;43(1):3–40.CrossRef
14.
go back to reference Garcia-Grimshaw M, Ceballos-Liceaga SE, Hernandez-Vanegas LE, Nunez I, Hernandez-Valdivia N, Carrillo-Garcia DA, et al. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: a nationwide descriptive study. Clin Immunol. 2021;229:108786.CrossRefPubMedCentral Garcia-Grimshaw M, Ceballos-Liceaga SE, Hernandez-Vanegas LE, Nunez I, Hernandez-Valdivia N, Carrillo-Garcia DA, et al. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: a nationwide descriptive study. Clin Immunol. 2021;229:108786.CrossRefPubMedCentral
15.
go back to reference Gobel CH, Heinze A, Karstedt S, Morscheck M, Tashiro L, Cirkel A, et al. Headache attributed to vaccination against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study. Pain Ther. 2021;10(2):1309–30.CrossRefPubMedCentral Gobel CH, Heinze A, Karstedt S, Morscheck M, Tashiro L, Cirkel A, et al. Headache attributed to vaccination against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study. Pain Ther. 2021;10(2):1309–30.CrossRefPubMedCentral
16.
go back to reference Gobel CH, Heinze A, Karstedt S, Morscheck M, Tashiro L, Cirkel A, et al. Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. Brain Commun. 2021;3(3):fcab169.CrossRefPubMedCentral Gobel CH, Heinze A, Karstedt S, Morscheck M, Tashiro L, Cirkel A, et al. Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. Brain Commun. 2021;3(3):fcab169.CrossRefPubMedCentral
17.
go back to reference Palaiodimou L, Stefanou MI, Katsanos AH, Aguiar de Sousa D, Coutinho JM, Lagiou P, et al. Cerebral Venous Sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: a systematic review and meta-analysis. Neurology. 2021;97(21):e2136–47.CrossRef Palaiodimou L, Stefanou MI, Katsanos AH, Aguiar de Sousa D, Coutinho JM, Lagiou P, et al. Cerebral Venous Sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: a systematic review and meta-analysis. Neurology. 2021;97(21):e2136–47.CrossRef
18.
go back to reference Sanchez van Kammen M, Aguiar de Sousa D, Poli S, Cordonnier C, Heldner MR, van de Munckhof A, et al. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. JAMA Neurol. 2021;78(11):1314–23.CrossRef Sanchez van Kammen M, Aguiar de Sousa D, Poli S, Cordonnier C, Heldner MR, van de Munckhof A, et al. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. JAMA Neurol. 2021;78(11):1314–23.CrossRef
19.
go back to reference Hameed S, Khan AF, Khan S, Wasay M. First Report of Cerebral Venous Thrombosis Following Inactivated-Virus Covid Vaccination (Sinopharm and Sinovac). J Stroke Cerebrovasc Dis. 2022;31(3): 106298.CrossRef Hameed S, Khan AF, Khan S, Wasay M. First Report of Cerebral Venous Thrombosis Following Inactivated-Virus Covid Vaccination (Sinopharm and Sinovac). J Stroke Cerebrovasc Dis. 2022;31(3): 106298.CrossRef
20.
go back to reference Organization WH. Immunization stress-related response: a manual for program managers and health professionals to prevent, identify and respond to stress-related responses following immunization. 2019. Organization WH. Immunization stress-related response: a manual for program managers and health professionals to prevent, identify and respond to stress-related responses following immunization. 2019.
21.
go back to reference Ercoli T, Lutzoni L, Orofino G, Muroni A, Defazio G. Functional neurological disorder after COVID-19 vaccination. Neurol Sci. 2021;42(10):3989–90.CrossRefPubMedCentral Ercoli T, Lutzoni L, Orofino G, Muroni A, Defazio G. Functional neurological disorder after COVID-19 vaccination. Neurol Sci. 2021;42(10):3989–90.CrossRefPubMedCentral
22.
go back to reference Hause AM, Gee J, Johnson T, Jazwa A, Marquez P, Miller E, et al. Anxiety-related adverse event clusters after Janssen COVID-19 vaccination five U S mass vaccination sites April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):685–8.CrossRef Hause AM, Gee J, Johnson T, Jazwa A, Marquez P, Miller E, et al. Anxiety-related adverse event clusters after Janssen COVID-19 vaccination five U S mass vaccination sites April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):685–8.CrossRef
23.
go back to reference Espay AJ, Aybek S, Carson A, Edwards MJ, Goldstein LH, Hallett M, et al. Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. JAMA Neurol. 2018;75(9):1132–41.CrossRefPubMedCentral Espay AJ, Aybek S, Carson A, Edwards MJ, Goldstein LH, Hallett M, et al. Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. JAMA Neurol. 2018;75(9):1132–41.CrossRefPubMedCentral
24.
go back to reference Gasca-Salas C, Lang AE. Neurologic diagnostic criteria for functional neurologic disorders. Handb Clin Neurol. 2016;139:193–212.CrossRef Gasca-Salas C, Lang AE. Neurologic diagnostic criteria for functional neurologic disorders. Handb Clin Neurol. 2016;139:193–212.CrossRef
25.
go back to reference Butler M, Coebergh J, Safavi F, Carson A, Hallett M, Michael B, et al. Functional neurological disorder after SARS-CoV-2 vaccines: two case reports and discussion of potential public health implications. J Neuropsychiatry Clin Neurosci. 2021;33(4):345–8.CrossRef Butler M, Coebergh J, Safavi F, Carson A, Hallett M, Michael B, et al. Functional neurological disorder after SARS-CoV-2 vaccines: two case reports and discussion of potential public health implications. J Neuropsychiatry Clin Neurosci. 2021;33(4):345–8.CrossRef
Metadata
Title
Inactivated COVID-19 vaccine induced acute stroke-like focal neurologic symptoms: a case series
Authors
Duangnapa Roongpiboonsopit
Chichaya Nithisathienchai
Wasan Akarathanawat
Krittanon Lertutsahakul
Jarturon Tantivattana
Anand Viswanathan
Nijasri Charnnarong Suwanwela
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2022
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-022-02739-6

Other articles of this Issue 1/2022

BMC Neurology 1/2022 Go to the issue